A nasal metoclopramide spray is expected to become a new option for the treatment of diabetic gastroparesis.
The spray, recently tested in a Phase III trial, avoids the problems of absorption inherent with an oral medication. Compared with the oral form, the nasal spray acts topically, avoiding the need for absorption, which may be impaired when gastrointestinal transit is delayed.
“In the clinical studies, the adverse event rates have been the same as placebo, and we think this method of